The holy grail of pharmacogenomics would be to determine alternative drugs or different doses of the same medication that should be used, based upon the patient's own genetic profile and how they process the drug. The difficulty in getting there, though, is still a problem.
Even predicting in whom the reaction will occur is of benefit, because in our very large provinces, getting people for routine testing, for cardiac testing, from the Queen Charlotte Islands, for example, is a bit of a problem for us, getting them all the way down to Vancouver. We sometimes can't get them to Vancouver for cardiac testing, so we have to wait until their next scheduled visit. If we knew predictably that they were at a higher risk of a reaction, we'd ensure we did more routine testing, and perhaps even have testing facilities and the right kinds of qualified professionals in a closer location to where they live so that could be done routinely.